The startup has developed a biotech platform that utilizes novel drug delivery systems and targeted therapeutic mechanisms to treat underactive bladder (UAB). This approach minimizes side effects while enhancing the efficacy of medications, ultimately improving patient symptoms and quality of life.
Funding
$5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Underactive bladder (UAB) is a condition characterized by the bladder's inability to contract properly, leading to incomplete emptying and a range of debilitating symptoms. Current treatments often lack efficacy and are associated with significant side effects, limiting their long-term use and impacting patient quality of life.
Solution
This startup is developing a biotech platform focused on treating underactive bladder (UAB) through advanced drug delivery systems and targeted therapeutic mechanisms. The platform aims to enhance medication efficacy while minimizing systemic exposure, thereby reducing adverse effects. By precisely targeting the bladder, the technology seeks to restore normal bladder function, improve emptying, and alleviate the symptoms associated with UAB. This targeted approach promises to offer a more effective and tolerable treatment option for patients suffering from this condition.
Target Audience
The primary target audience includes individuals diagnosed with underactive bladder (UAB) and healthcare providers specializing in urology and bladder dysfunction.
Features
- Novel drug delivery system for targeted administration to the bladder.
- Therapeutic mechanisms designed to stimulate bladder contractility.
- Formulation designed to minimize systemic drug exposure and off-target effects.